Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia

References

• Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Prac Res Clin Haematol. 2010;23:145–53. doi:10.1016/j.beha.2009.12.004.
   PubMed Web of Science ®Google Scholar
• Linet MS, Schubauer-Berigan MK, Weisenburger DD, Richardson DB, Landgren O, Blair A, Silver S, Field RW, Caldwell G, Hatch M, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol. 2007;139:672–86. doi:10.1111/j.1365-2141.2007.06847.x.
   PubMed Web of Science ®Google Scholar
• Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136–41. doi:10.1038/leu.2012.187.
   PubMed Web of Science ®Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. ASH Educ Prog Book. 2008;2008:450–56.
   Google Scholar
• Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509–13.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1730–33. doi:10.3109/10428194.2012.750723.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81. doi:10.1182/blood-2015-03-567388.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Vinolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. natural history and prognostic significance. Cancer. 1988;61:279–83.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9:2505–23. doi:10.4161/hv.26109.
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Aittoniemi J, Oivanen P, Käyhty H, Ölander R, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114:107–10.
   PubMed Web of Science ®Google Scholar
• Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671–77.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O’Brien S, Koller CA, Bodey GP, Keating MJ. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: A prospective, randomized trial of safety and immunogenicity. Cancer. 2008;113:383–87. doi:10.1002/cncr.23561.
   PubMed Web of Science ®Google Scholar
• Van der Velden AM, Van Velzen-Blad H, Claessen AM, Van der Griend R, Oltmans R, Rijkers GT, Biesma DH. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2007;79:47–52. doi:10.1111/j.1600-0609.2007.00862.x.
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26:82–87. doi:10.1016/j.vaccine.2007.10.053.
   PubMed Web of Science ®Google Scholar
• Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, Hus I, Malm A. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients–preliminary report. PLoS One. 2014;9:e114966. doi:10.1371/journal.pone.0114966.
   PubMed Web of Science ®Google Scholar
• Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson PO, Svensson M, Nilsson I, Rombo L, Cherif H, Kimby E. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the swedish CLL group. Vaccine. 2018;36:3701–07. doi:10.1016/j.vaccine.2018.05.012.
   PubMed Web of Science ®Google Scholar
• Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin’s disease. J Infect Dis. 1996;173:256–58. doi:10.1093/infdis/173.1.256.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V, Ribaud P, de Camara RL, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28:2730–34. doi:10.1016/j.vaccine.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R, Ullmann AJ, Parkkali T, Locasciulli A, Yakouben K, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401. doi:10.1086/598324.
   PubMed Web of Science ®Google Scholar
• Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, Itälä-Remes M, Sinisalo M. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2018;14:1471–74. doi:10.1080/21645515.2018.1436424.
   PubMed Web of Science ®Google Scholar
• Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol. 2008;15:1391–97. doi:10.1128/CVI.00110-08.
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, et al. . Vaccine. 2003;21:3265–72.
   PubMed Web of Science ®Google Scholar
• Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, Spoulou VS. Immunogenicity and immunological memory induced by the 13-valent pneumococcal conjugate followed by the 23-valent polysaccharide vaccine in HIV-infected adults. J Infect Dis. 2018;218:26–34. doi:10.1093/infdis/jiy135.
   PubMed Web of Science ®Google Scholar
• Papadatou I, Spoulou V. Pneumococcal vaccination in high-risk individuals: are we doing it right? Clin Vaccine Immunol. 2016;23:388–95. doi:10.1128/CVI.00721-15.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;34:944–47. doi:10.15585/mmwr.mm6434a4.
   Web of Science ®Google Scholar
• Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the basic and clinical immunology interest section of the american academy of allergy, asthma & immunology. J Allergy Clin Immunol. 2012;130:S1–24. doi:10.1016/j.jaci.2012.07.002.
   PubMed Web of Science ®Google Scholar